PETRUZZO, MARTINA
 Distribuzione geografica
Continente #
NA - Nord America 349
AS - Asia 130
EU - Europa 116
AF - Africa 18
OC - Oceania 1
Totale 614
Nazione #
US - Stati Uniti d'America 345
SG - Singapore 57
IT - Italia 55
HK - Hong Kong 40
CN - Cina 22
CI - Costa d'Avorio 18
NL - Olanda 16
DE - Germania 14
IN - India 10
GB - Regno Unito 8
RU - Federazione Russa 7
FI - Finlandia 5
CA - Canada 4
SE - Svezia 4
BE - Belgio 2
UA - Ucraina 2
AT - Austria 1
AU - Australia 1
FR - Francia 1
LA - Repubblica Popolare Democratica del Laos 1
PL - Polonia 1
Totale 614
Città #
Chandler 68
Santa Clara 54
Singapore 43
Hong Kong 40
Amsterdam 16
Ashburn 16
Millbury 12
Lawrence 11
Des Moines 8
Wilmington 8
Boston 7
Naples 7
Dallas 6
Milan 6
Seattle 5
Helsinki 4
Munich 4
Beijing 3
Chengdu 3
Moscow 3
Rome 3
Segrate 3
Verona 3
Brussels 2
Falkenstein 2
Grottaferrata 2
Hefei 2
Jiaxing 2
Los Angeles 2
Montalbano Jonico 2
Napoli 2
Ottawa 2
Pune 2
Stockholm 2
Ann Arbor 1
Bellona 1
Borås 1
Brusciano 1
Caserta 1
Edinburgh 1
Fairfield 1
Frankfurt am Main 1
Kronberg 1
Lappeenranta 1
Leawood 1
Marano 1
Montechiarugolo 1
Montreal 1
Nanjing 1
Paris 1
Pingxiang 1
Pisticci 1
Pozzuoli 1
Princeton 1
Qingyuan 1
Richmond 1
San Diego 1
Sydney 1
Terzigno 1
Varese 1
Vientiane 1
Warsaw 1
Washington 1
Woodbridge 1
Wuhan 1
Totale 386
Nome #
The impact of diagnostic criteria and treatments on the 20-year costs for treating relapsing-remitting multiple sclerosis 47
Online validation of the Italian version of the patient determined disease steps scale (PDDS) in people with multiple sclerosis 46
Cognitive trajectories in multiple sclerosis: a long-term follow-up study 46
A multiple n-glucosylated peptide epitope efficiently detecting antibodies in multiple sclerosis 45
Peripapillary Vessel Density as Early Biomarker in Multiple Sclerosis 44
COVID-19 pandemic and mental distress in Multiple Sclerosis: implications for clinical management 41
Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study 38
A retrospective exploratory analysis on cardiovascular risk and cognitive dysfunction in multiple sclerosis 38
MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study 34
Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved? 34
Asymptomatic bradycardia after first fingolimod dose in a pediatric patient with multiple sclerosis - a case report 32
Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study 32
Multiple Sclerosis in the Campania Region (South Italy): Algorithm Validation and 2015-2017 Prevalence 31
The Framingham cardiovascular risk score and 5-year progression of multiple sclerosis 31
Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis 30
Predictors of Nabiximols (Sativex®) discontinuation over long-term follow-up: a real-life study 29
Digital Technology in Clinical Trials for Multiple Sclerosis: Systematic Review 23
Single-Center 8-Years Clinical Follow-Up of Cladribine-Treated Patients From Phase 2 and 3 Trials 18
Correction to: Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study (Journal of Neurology, (2022), 269, 6, (3301-3307), 10.1007/s00415-022-11009-x) 12
Digital Technology in Clinical Trials for Multiple Sclerosis: a systematic review. (Preprint) 3
Totale 654
Categoria #
all - tutte 3.515
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.515


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202020 0 0 0 0 0 0 0 4 0 8 8 0
2020/202143 6 5 4 18 3 1 0 0 3 1 0 2
2021/202270 2 0 1 1 1 5 1 5 1 7 18 28
2022/2023188 12 12 4 8 22 32 2 22 42 19 12 1
2023/202496 4 16 8 1 8 9 3 22 2 2 13 8
2024/2025228 25 29 3 12 43 64 52 0 0 0 0 0
Totale 654